DFTX stock forecast, quote, news & analysis
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction... Show more
Why Definium Therapeutics (DFTX) Stock Is Down -11.7% in the Last 30 Days
Key Takeaways
- DFTX shares declined approximately 11.7% over the trailing 30 days, from $40.98 to $36.17, extending a pullback from the early-August 52-week high of $49.70.
- The drop came despite a third consecutive positive Phase 3 readout, as investors locked in gains after a roughly 300% 12-month rally.
- Definium Therapeutics, formerly Mind Medicine (MindMed), is advancing DT120 ODT, an LSD-derived (lysergide) orally disintegrating tablet, through late-stage trials in generalized anxiety disorder (GAD) and major depressive disorder (MDD).
- Analyst sentiment remains constructive, with Baird raising its price target to $79 from $75 following the latest results.
- The stock remains far above its 52-week low of $8.77, carrying a market capitalization of roughly $5.2 billion for a pre-revenue, clinical-stage company.
Definium Therapeutics (DFTX) Company Overview and Market Position
Definium Therapeutics is a late-stage clinical biopharmaceutical company headquartered in New York that is developing a new generation of psychedelic-derived therapeutics for psychiatric and neurological disorders. The company was previously known as Mind Medicine (MindMed) and adopted the DFTX ticker in January 2026 as part of its rebranding.
Its lead candidate, DT120 ODT (formerly MM-120), is a pharmaceutically optimized, orally disintegrating tablet formulation of lysergide D-tartrate (LSD) being developed for GAD and MDD. DT120 has received FDA Breakthrough Therapy Designation in GAD. The company is also advancing DT402 (R(-)-MDMA) for autism spectrum disorder. Because Definium is pre-revenue and still clinical-stage, its valuation is driven primarily by clinical data, regulatory milestones, and the potential commercial opportunity in large neuropsychiatric markets.
Definium Therapeutics (DFTX) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, DFTX fell roughly 11.7%, from a closing price of $40.98 on August 28 to $36.17 on September 25. The move extended a broader retracement from the 52-week intraday high of $49.70 reached in early August.
The trailing quarter has been exceptionally volatile. Shares climbed from the mid-$20s in mid-June to the early-August peak as the company delivered positive data, before giving back a meaningful portion of those gains. Measured from a late-June close near $44.79, the stock is down approximately 19% over the quarter. Even so, DFTX remains sharply higher on a year-to-date basis, up roughly 190% from the start of 2026.
What Drove DFTX Stock Price in the Last 30 Days
On September 14, 2026, Definium announced positive topline results from the Panorama Phase 3 trial of DT120 ODT in GAD. The study met its primary endpoint, showing a 5.1-point placebo-adjusted improvement on the Hamilton Anxiety Rating Scale (HAM-A) at week 12 (p<0.0001), with statistically significant results on all key secondary endpoints.
Despite the favorable data, shares sold off in the days that followed. The pullback largely reflected a "sell-the-news" dynamic: clinical success had already been widely anticipated after the prior Emerge (MDD) and Voyage (GAD) readouts, and the shares had run up sharply in advance. With the stock carrying a roughly $5.2 billion valuation for a company with no current revenue, investors took profits as the third positive result removed a key near-term catalyst.
Additional factors included insider selling, with roughly $5 million in insider sales reported over the prior 12 months and a tax-related sale by the chief executive in early September. Baird's September 15 decision to raise its price target to $79 from $75, while positive, was not enough to offset the profit-taking.
What Drove DFTX Stock Performance Over the Last Quarter
The quarter's narrative was defined by a rapid de-risking of the clinical pipeline. Positive topline results from the Emerge Phase 3 study in MDD in late June triggered a sharp rally from the mid-$20s, and positive Voyage results in GAD in August pushed shares to a 52-week high of $49.70. The September Panorama readout completed a third consecutive positive Phase 3 outcome for DT120 ODT.
As the pivotal data set came together, the market's focus shifted from clinical risk to execution, valuation, and regulatory timelines. The subsequent retracement reflected a normalization from elevated levels rather than any deterioration in the underlying clinical story, with profit-taking and the absence of near-term binary catalysts weighing on the shares.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots. Tickeron offers hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots are featured in this section. These bots vary widely in strategy, timeframe, and performance metrics, giving traders a range of approaches to explore. The section is designed to help users identify AI trading tools that are currently generating strong signals across the market. For investors tracking volatile, catalyst-driven names like Definium Therapeutics, exploring these AI-driven tools can offer an additional perspective on market behavior.
DFTX Stock Forecast Drivers: What Investors Should Watch Next
Several developments are likely to shape DFTX's trajectory in the months ahead. The company has guided to a pre-NDA meeting with the FDA in the fourth quarter of 2026 and a planned New Drug Application submission in the first half of 2027, which would be a pivotal regulatory milestone for DT120 ODT.
Investors should also monitor enrollment progress in the Ascend Phase 3 MDD study, initial data from the DT402 Phase 2a trial in autism spectrum disorder, and any updates on commercial-readiness preparations. Broader factors include analyst price-target revisions, regulatory developments around psychedelic therapies, the company's cash runway and potential future financings, and ongoing insider selling activity. As with all clinical-stage biotechnology companies, execution and regulatory outcomes carry meaningful risk and remain the primary drivers of value.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
DFTX sees its Stochastic Oscillator ascends from oversold territory
On September 29, 2026, the Stochastic Oscillator for DFTX moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 59 instances where the indicator left the oversold zone. In 54 of the 59 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for DFTX just turned positive on September 28, 2026. Looking at past instances where DFTX's MACD turned positive, the stock continued to rise in 38 of 43 cases over the following month. The odds of a continued upward trend are 88%.
Following a +3.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where DFTX advanced for three days, in 238 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
DFTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DFTX as a result. In 75 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.
DFTX moved below its 50-day moving average on August 28, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for DFTX crossed bearishly below the 50-day moving average on September 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DFTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for DFTX entered a downward trend on October 01, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. DFTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.618) is normal, around the industry mean (26.780). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DFTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology